首页 > 最新文献

Current diabetes reviews最新文献

英文 中文
Dating Violence, Lifestyle and Risk of Type 2 Diabetes in Mexican Women University Students. 墨西哥女大学生的约会暴力、生活方式和 2 型糖尿病风险。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998283227240117060452
Geu Mendoza-Catalan, Jose Alfredo Pimentel-Jaimes, Erika Nallely Orendain-Jaime, Claudia Jennifer Dominguez-Chavez, Jose Luis Higuera-Sainz, Alma Angelica Villa-Rueda, Ulises Rieke-Campoy, Adriana Camargo-Bravo

Background: Dating violence is a prevalent issue among Mexican women, as is the incidence and prevalence of Type 2 diabetes mellitus (T2DM). The effects of dating violence can negatively impact lifestyle and, consequently, increase the risk of T2DM.

Objective: This study aimed to explore the influence of dating violence on lifestyle and the risk of T2DM in women university students from Mexico.

Methods: The study employed a cross-sectional and correlational design. The study population consisted of women university students. The sample size included 255 participants. Women aged 18 to 39 with current dating relationships and residency in Mexicali, Baja California, Mexico, were included. Data collection was conducted from February to May 2023. Correlations and multiple linear regression models were conducted.

Results: A total of 255 women participated, with an average age of 21.6 years (SD = 3.2), and 32.2% had a history of intrafamily violence during childhood. 58.8% of the participants exhibited some level of risk of T2DM, and 56.7% of the lifestyle was mostly categorized as poor/fair. Detachment was the most prevalent type of dating violence, followed by coercion. Dating violence was correlated with lifestyle (r = -.430) and the risk of T2DM (r = .321). In the multiple linear regression model, dating violence influenced the risk of T2DM.

Conclusion: Women who reported higher levels of dating violence have a less healthy lifestyle and a greater risk of T2DM. It is important to consider dating violence to improve lifestyle and prevent T2DM in Mexican women university students.

背景:在墨西哥妇女中,约会暴力是一个普遍存在的问题,2 型糖尿病(T2DM)的发病率和流行率也是如此。约会暴力的影响会对生活方式产生负面影响,从而增加罹患 T2DM 的风险:本研究旨在探讨约会暴力对生活方式的影响以及墨西哥女大学生患 T2DM 的风险:研究采用横断面和相关性设计。研究对象包括女大学生。样本量包括 255 名参与者。研究对象包括年龄在 18 至 39 岁之间、目前有约会关系、居住在墨西哥下加利福尼亚州墨西卡利市的女性。数据收集时间为 2023 年 2 月至 5 月。研究采用了相关性和多元线性回归模型:共有 255 名女性参与,平均年龄为 21.6 岁(SD = 3.2),32.2% 的女性在童年时期有过家庭暴力史。58.8%的参与者表现出某种程度的 T2DM 风险,56.7%的生活方式主要被归类为不良/一般。疏远是最常见的约会暴力类型,其次是胁迫。约会暴力与生活方式(r = -.430)和 T2DM 风险(r = .321)相关。在多元线性回归模型中,约会暴力影响了罹患 T2DM 的风险:结论:报告约会暴力程度较高的女性的生活方式不太健康,患 T2DM 的风险较大。考虑约会暴力对于改善墨西哥女大学生的生活方式和预防 T2DM 非常重要。
{"title":"Dating Violence, Lifestyle and Risk of Type 2 Diabetes in Mexican Women University Students.","authors":"Geu Mendoza-Catalan, Jose Alfredo Pimentel-Jaimes, Erika Nallely Orendain-Jaime, Claudia Jennifer Dominguez-Chavez, Jose Luis Higuera-Sainz, Alma Angelica Villa-Rueda, Ulises Rieke-Campoy, Adriana Camargo-Bravo","doi":"10.2174/0115733998283227240117060452","DOIUrl":"10.2174/0115733998283227240117060452","url":null,"abstract":"<p><strong>Background: </strong>Dating violence is a prevalent issue among Mexican women, as is the incidence and prevalence of Type 2 diabetes mellitus (T2DM). The effects of dating violence can negatively impact lifestyle and, consequently, increase the risk of T2DM.</p><p><strong>Objective: </strong>This study aimed to explore the influence of dating violence on lifestyle and the risk of T2DM in women university students from Mexico.</p><p><strong>Methods: </strong>The study employed a cross-sectional and correlational design. The study population consisted of women university students. The sample size included 255 participants. Women aged 18 to 39 with current dating relationships and residency in Mexicali, Baja California, Mexico, were included. Data collection was conducted from February to May 2023. Correlations and multiple linear regression models were conducted.</p><p><strong>Results: </strong>A total of 255 women participated, with an average age of 21.6 years (SD = 3.2), and 32.2% had a history of intrafamily violence during childhood. 58.8% of the participants exhibited some level of risk of T2DM, and 56.7% of the lifestyle was mostly categorized as poor/fair. Detachment was the most prevalent type of dating violence, followed by coercion. Dating violence was correlated with lifestyle (r = -.430) and the risk of T2DM (r = .321). In the multiple linear regression model, dating violence influenced the risk of T2DM.</p><p><strong>Conclusion: </strong>Women who reported higher levels of dating violence have a less healthy lifestyle and a greater risk of T2DM. It is important to consider dating violence to improve lifestyle and prevent T2DM in Mexican women university students.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e300124226536"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes Mellitus. 与内脏脂肪有关的成纤维细胞生长因子 21 (FGF21) 功能受损导致胰岛素抵抗:糖尿病的核心缺陷。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998265915231116043813
Unnati Jain, Priyanka Srivastava, Ashwani Sharma, Subrata Sinha, Surabhi Johari

The Central nervous system (CNS) is the prime regulator of signaling pathways whose function includes regulation of food intake (consumption), energy expenditure, and other metabolic responses like glycolysis, gluconeogenesis, fatty acid oxidation, and thermogenesis that have been implicated in chronic inflammatory disorders. Type 2 diabetes mellitus (T2DM) and obesity are two metabolic disorders that are linked together and have become an epidemic worldwide, thus raising significant public health concerns. Fibroblast growth factor 21 (FGF21) is an endocrine hormone with pleiotropic metabolic effects that increase insulin sensitivity and energy expenditure by elevating thermogenesis in brown or beige adipocytes, thus reducing body weight and sugar intake. In contrast, during starvation conditions, FGF21 induces its expression in the liver to initiate glucose homeostasis. Insulin resistance is one of the main anomalies caused by impaired FGF21 signaling, which also causes abnormal regulation of other signaling pathways. Tumor necrosis factor alpha (TNF-α), the cytokine released by adipocytes and inflammatory cells in response to chronic inflammation, is regarded major factor that reduces the expression of FGF21 and modulates underlying insulin resistance that causes imbalanced glucose homeostasis. This review aims to shed light on the mechanisms underlying the development of insulin resistance in obese individuals as well as the fundamental flaw in type 2 diabetes, which is malfunctioning obese adipose tissue.

中枢神经系统(CNS)是信号通路的主要调节器,其功能包括调节食物摄入(消耗)、能量消耗和其他代谢反应,如糖酵解、糖代谢、脂肪酸氧化和产热,这些都与慢性炎症性疾病有关。2 型糖尿病(T2DM)和肥胖症是两种相互关联的代谢性疾病,它们已成为世界范围内的流行病,从而引发了重大的公共卫生问题。成纤维细胞生长因子 21(FGF21)是一种内分泌激素,具有多种代谢效应,可通过提高棕色或米色脂肪细胞的产热增加胰岛素敏感性和能量消耗,从而降低体重和糖摄入量。相反,在饥饿条件下,FGF21 会诱导其在肝脏中的表达,以启动葡萄糖稳态。胰岛素抵抗是 FGF21 信号传导受损导致的主要异常现象之一,它还会导致其他信号传导途径的调节异常。肿瘤坏死因子α(TNF-α)是脂肪细胞和炎症细胞为应对慢性炎症而释放的细胞因子,是降低 FGF21 表达和调节潜在胰岛素抵抗的主要因素,而胰岛素抵抗会导致葡萄糖平衡失衡。本综述旨在阐明肥胖者胰岛素抵抗的发展机制以及 2 型糖尿病的根本缺陷,即肥胖脂肪组织功能失调。
{"title":"Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes Mellitus.","authors":"Unnati Jain, Priyanka Srivastava, Ashwani Sharma, Subrata Sinha, Surabhi Johari","doi":"10.2174/0115733998265915231116043813","DOIUrl":"10.2174/0115733998265915231116043813","url":null,"abstract":"<p><p>The Central nervous system (CNS) is the prime regulator of signaling pathways whose function includes regulation of food intake (consumption), energy expenditure, and other metabolic responses like glycolysis, gluconeogenesis, fatty acid oxidation, and thermogenesis that have been implicated in chronic inflammatory disorders. Type 2 diabetes mellitus (T2DM) and obesity are two metabolic disorders that are linked together and have become an epidemic worldwide, thus raising significant public health concerns. Fibroblast growth factor 21 (FGF21) is an endocrine hormone with pleiotropic metabolic effects that increase insulin sensitivity and energy expenditure by elevating thermogenesis in brown or beige adipocytes, thus reducing body weight and sugar intake. In contrast, during starvation conditions, FGF21 induces its expression in the liver to initiate glucose homeostasis. Insulin resistance is one of the main anomalies caused by impaired FGF21 signaling, which also causes abnormal regulation of other signaling pathways. Tumor necrosis factor alpha (TNF-α), the cytokine released by adipocytes and inflammatory cells in response to chronic inflammation, is regarded major factor that reduces the expression of FGF21 and modulates underlying insulin resistance that causes imbalanced glucose homeostasis. This review aims to shed light on the mechanisms underlying the development of insulin resistance in obese individuals as well as the fundamental flaw in type 2 diabetes, which is malfunctioning obese adipose tissue.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e260424229342"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of Type 1 Diabetes Mellitus in SARS-CoV-2 Patients. SARS CoV-2 患者罹患 1 型糖尿病的风险。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998290807240522045553
Shweta Chahal, Rojin G Raj, Ranjeet Kumar

Recent studies have found that a link between people with type 1 diabetes mellitus (T1DM) are at higher risk of morbidity as well as mortality from COVID-19 infection, indicating a need for vaccination. T1DM appears to impair innate and adaptive immunity. The overabundance of pro-inflammatory cytokines produced in COVID-19 illness that is severe and potentially fatal is known as a "cytokine storm." Numerous cohorts have revealed chronic inflammation as a key risk factor for unfavorable COVID-19 outcomes. TNF-α, interleukin (IL)-1a, IL-1, IL-2, IL-6, and other cytokines were found in higher concentrations in patients with T1DM. Even more importantly, oxidative stress contributes significantly to the severity and course of COVID- 19's significant role in the progression and severity of COVID-19 diseases. Severe glucose excursions, a defining characteristic of type 1 diabetes, are widely recognized for their potent role as mediating agents of oxidative stress via several routes, such as heightened production of advanced glycation end products (AGEs) and activation of protein kinase C (PKC). Furthermore, persistent endothelial dysfunction and hypercoagulation found in T1DM may impair microcirculation and endothelium, which could result in the development of various organ failure and acute breathing syndrome.

最近的研究发现,1 型糖尿病(T1DM)患者因感染 COVID-19 而发病和死亡的风险较高,这表明有必要接种疫苗。T1DM 似乎会损害先天性免疫和适应性免疫。COVID-19 病症严重并可能致命时,会产生过量的促炎细胞因子,这就是所谓的 "细胞因子风暴"。大量队列研究表明,慢性炎症是导致 COVID-19 不幸结局的关键风险因素。在 T1DM 患者中,TNF-α、白细胞介素 (IL)-1a、IL-1、IL-2、IL-6 和其他细胞因子的浓度较高。更重要的是,氧化应激对 COVID-19 疾病的严重程度和病程起着重要作用。严重的血糖偏高是 1 型糖尿病的一个显著特征,其作为氧化应激介质的强大作用已得到广泛认可,氧化应激可通过多种途径产生,如增加高级糖化终产物(AGEs)的产生和激活蛋白激酶 C(PKC)。此外,T1DM 中持续存在的内皮功能障碍和高凝状态可能会损害微循环和内皮,从而导致各种器官衰竭和急性呼吸综合征。
{"title":"Risk of Type 1 Diabetes Mellitus in SARS-CoV-2 Patients.","authors":"Shweta Chahal, Rojin G Raj, Ranjeet Kumar","doi":"10.2174/0115733998290807240522045553","DOIUrl":"10.2174/0115733998290807240522045553","url":null,"abstract":"<p><p>Recent studies have found that a link between people with type 1 diabetes mellitus (T1DM) are at higher risk of morbidity as well as mortality from COVID-19 infection, indicating a need for vaccination. T1DM appears to impair innate and adaptive immunity. The overabundance of pro-inflammatory cytokines produced in COVID-19 illness that is severe and potentially fatal is known as a \"cytokine storm.\" Numerous cohorts have revealed chronic inflammation as a key risk factor for unfavorable COVID-19 outcomes. TNF-α, interleukin (IL)-1a, IL-1, IL-2, IL-6, and other cytokines were found in higher concentrations in patients with T1DM. Even more importantly, oxidative stress contributes significantly to the severity and course of COVID- 19's significant role in the progression and severity of COVID-19 diseases. Severe glucose excursions, a defining characteristic of type 1 diabetes, are widely recognized for their potent role as mediating agents of oxidative stress via several routes, such as heightened production of advanced glycation end products (AGEs) and activation of protein kinase C (PKC). Furthermore, persistent endothelial dysfunction and hypercoagulation found in T1DM may impair microcirculation and endothelium, which could result in the development of various organ failure and acute breathing syndrome.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e240524230298"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Probiotic Supplementation during Pregnancy: Evaluating the Current Clinical Evidence against Gestational Diabetes Mellitus. 孕期补充益生菌:评估目前针对妊娠糖尿病的临床证据。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998284749240417052006
Eleni Pavlidou, Olga Alexatou, Gerasimos Tsourouflis, Georgios Antasouras, Sousana K Papadopoulou, Dimitrios Papandreou, Anastasia Sampani, Constantinos Giaginis

Background: Gestational diabetes mellitus (GDM) constitutes a common metabolic disorder that could lead to deleterious short- and long-term complications in both the mother and her infant. Probiotic supplementation seems to exert diverse, healthy effects by acting as a preventive agent against various human diseases, including GDM.

Objective: The purpose of the current narrative review was to critically summarize and scrutinize the available clinical studies during the last 15 years (2008-2023) concerning the use of probiotic supplementation during pregnancy as a protecting agent against GDM.

Methods: A thorough and in-depth search was performed in the most accurate scientific databases, e.g., PubMed., Scopus, Web of Science, and Google Scholar applying effective, and relevant keywords.

Results: There are currently some clinical studies suggesting the potential beneficial impact of probiotic supplementation in the prevention and/or co-treatment of GDM. Nevertheless, there is a high heterogeneity amongst the available clinical studies concerning the dosage, the administration duration, the probiotic species types, the method designs and protocols, and the study populations.

Conclusion: Probiotic supplementation at conventional dosages and in combination with a balanced healthy diet, and lifestyle seems to reduce the the risk of developing GDM, while ameliorating the severity of its symptoms. Further clinical studies taking into account the above considerations should be performed to establish conclusive results, while the future meta-analyses should include studies with the feasibly lowest heterogeneity.

背景:妊娠糖尿病(GDM)是一种常见的代谢紊乱疾病,可导致母婴短期和长期的有害并发症。补充益生菌可预防包括 GDM 在内的各种人类疾病,从而发挥多种多样的健康作用:本综述旨在对过去 15 年(2008-2023 年)中有关孕期补充益生菌作为 GDM 预防剂的临床研究进行批判性总结和仔细研究:方法:在最准确的科学数据库(如 PubMed、Scopus、Web of Science 和 Google Scholar)中应用有效的相关关键词进行了全面深入的搜索:结果:目前有一些临床研究表明,补充益生菌对预防和/或合并治疗 GDM 有潜在的益处。然而,现有的临床研究在剂量、给药时间、益生菌种类、方法设计和方案以及研究人群等方面存在很大的异质性:结论:按照常规剂量补充益生菌,并与均衡健康的饮食和生活方式相结合,似乎可以降低罹患 GDM 的风险,同时改善其症状的严重程度。为了得出最终结果,应在考虑上述因素的基础上开展进一步的临床研究,而未来的荟萃分析应包括异质性尽可能低的研究。
{"title":"Probiotic Supplementation during Pregnancy: Evaluating the Current Clinical Evidence against Gestational Diabetes Mellitus.","authors":"Eleni Pavlidou, Olga Alexatou, Gerasimos Tsourouflis, Georgios Antasouras, Sousana K Papadopoulou, Dimitrios Papandreou, Anastasia Sampani, Constantinos Giaginis","doi":"10.2174/0115733998284749240417052006","DOIUrl":"10.2174/0115733998284749240417052006","url":null,"abstract":"<p><strong>Background: </strong>Gestational diabetes mellitus (GDM) constitutes a common metabolic disorder that could lead to deleterious short- and long-term complications in both the mother and her infant. Probiotic supplementation seems to exert diverse, healthy effects by acting as a preventive agent against various human diseases, including GDM.</p><p><strong>Objective: </strong>The purpose of the current narrative review was to critically summarize and scrutinize the available clinical studies during the last 15 years (2008-2023) concerning the use of probiotic supplementation during pregnancy as a protecting agent against GDM.</p><p><strong>Methods: </strong>A thorough and in-depth search was performed in the most accurate scientific databases, e.g., PubMed., Scopus, Web of Science, and Google Scholar applying effective, and relevant keywords.</p><p><strong>Results: </strong>There are currently some clinical studies suggesting the potential beneficial impact of probiotic supplementation in the prevention and/or co-treatment of GDM. Nevertheless, there is a high heterogeneity amongst the available clinical studies concerning the dosage, the administration duration, the probiotic species types, the method designs and protocols, and the study populations.</p><p><strong>Conclusion: </strong>Probiotic supplementation at conventional dosages and in combination with a balanced healthy diet, and lifestyle seems to reduce the the risk of developing GDM, while ameliorating the severity of its symptoms. Further clinical studies taking into account the above considerations should be performed to establish conclusive results, while the future meta-analyses should include studies with the feasibly lowest heterogeneity.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e260424229418"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective. 糖尿病神经病变评估:治疗和神经生物学视角。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998290606240521113832
Bhanupriya Bhrigu, Shikha Sharma, Nitin Kumar, Bimal Krishna Banik

Diabetic neuropathy, also known as diabetic peripheral sensorimotor neuropathy (DPN), is a consequential complexity of diabetes, alongside diabetic nephropathy, diabetic cardiomyopathy, and diabetic retinopathy. It is characterized by signs and symptoms of peripheral nerve damage in diabetes patients after ruling out other causes. Approximately 20% of people with diabetes are affected by this painful and severe condition. The development of diabetic neuropathy is influenced by factors such as impaired blood flow to the peripheral nerves and metabolic issues, including increased polyol pathway activation, myo-inositol loss, and nonenzymatic glycation. The present review article provides a brief overview of the pathological changes in diabetic neuropathy and the mechanisms and types of DPN. Various diagnostic tests and biomarkers are available to assess nerve damage and its severity. Pharmacotherapy for neuropathic pain in diabetic neuropathy is complex. This review will explore current treatment options and potential future developments to improve the quality of life for patients suffering from diabetic neuropathy.

糖尿病神经病变又称糖尿病周围感觉运动神经病变(DPN),是糖尿病的一种并发症,与糖尿病肾病、糖尿病心肌病和糖尿病视网膜病变并称为糖尿病的三大并发症。其特征是糖尿病患者在排除其他病因后出现周围神经损伤的症状和体征。约有 20% 的糖尿病患者会受到这种痛苦而严重的病症的影响。糖尿病神经病变的发生受多种因素的影响,如周围神经血流受损和代谢问题,包括多元醇通路激活增加、肌醇损失和非酶糖化。本综述文章简要概述了糖尿病神经病变的病理变化以及 DPN 的机制和类型。目前有多种诊断测试和生物标志物可用于评估神经损伤及其严重程度。糖尿病神经病变中神经病理性疼痛的药物治疗非常复杂。本综述将探讨当前的治疗方案和未来的潜在发展,以改善糖尿病神经病变患者的生活质量。
{"title":"Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.","authors":"Bhanupriya Bhrigu, Shikha Sharma, Nitin Kumar, Bimal Krishna Banik","doi":"10.2174/0115733998290606240521113832","DOIUrl":"10.2174/0115733998290606240521113832","url":null,"abstract":"<p><p>Diabetic neuropathy, also known as diabetic peripheral sensorimotor neuropathy (DPN), is a consequential complexity of diabetes, alongside diabetic nephropathy, diabetic cardiomyopathy, and diabetic retinopathy. It is characterized by signs and symptoms of peripheral nerve damage in diabetes patients after ruling out other causes. Approximately 20% of people with diabetes are affected by this painful and severe condition. The development of diabetic neuropathy is influenced by factors such as impaired blood flow to the peripheral nerves and metabolic issues, including increased polyol pathway activation, myo-inositol loss, and nonenzymatic glycation. The present review article provides a brief overview of the pathological changes in diabetic neuropathy and the mechanisms and types of DPN. Various diagnostic tests and biomarkers are available to assess nerve damage and its severity. Pharmacotherapy for neuropathic pain in diabetic neuropathy is complex. This review will explore current treatment options and potential future developments to improve the quality of life for patients suffering from diabetic neuropathy.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"12-31"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Machine Learning and Artificial Intelligence to Predict Diabetes Mellitus among Women Population. 利用机器学习和人工智能预测女性糖尿病。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/1573399820666230605160212
Ali Mamoon Alfalki

Background: Diabetes Mellitus is a chronic health condition (long-lasting) due to inadequate control of blood levels of glucose. This study presents a prediction of Type 2 Diabetes Mellitus among women using various Machine Learning Algorithms deployed to predict the diabetic condition. A University of California Irvine Diabetes Mellitus Dataset posted in Kaggle was used for analysis.

Methods: The dataset included eight risk factors for Type 2 Diabetes Mellitus prediction, including Age, Systolic Blood Pressure, Glucose, Body Mass Index, Insulin, Skin Thickness, Diabetic Pedigree Function, and Pregnancy. R language was used for the data visualization, while the algorithms considered for the study are Logistic Regression, Support Vector Machines, Decision Trees and Extreme Gradient Boost. The performance analysis of these algorithms on various classification metrics is also presented here, considering the Area Under the Curve and Receiver Operating Characteristics score is the best for Extreme Gradient Boost with 85%, followed by Support Vector Machines and Decision Trees.

Results: The Logistic Regression is showing low performance. But the Decision Trees and Extreme Gradient Boost show promising performance against all the classification metrics. But the Support Vector Machines offers a lower support value; hence it cannot be claimed to be a good classifier. The model showed that the most significant predictors of Type 2 Diabetes Mellitus were strongly correlated with Glucose Levels and mediumly correlated with Body Mass Index, whereas Age, Skin Thickness, Systolic Blood Pressure, Insulin, Pregnancy, and Pedigree Function were less significant. This type of real-time analysis has proved that the symptoms of Type 2 Diabetes Mellitus in women fall entirely different compared to men, which highlights the importance of Glucose Levels and Body Mass Index in women.

Conclusion: The prediction of Type 2 Diabetes Mellitus helps public health professionals to help people by suggesting proper food intake and adjusting lifestyle activities with good fitness management in women to make glucose levels and body mass index controlled. Therefore, the healthcare systems should give special attention to diabetic conditions in women to reduce exacerbations of the disease and other associated symptoms. This work attempts to predict the occurrence of Type 2 Diabetes Mellitus among women on their behavioral and biological conditions.

背景:糖尿病是一种慢性健康状况(长期)由于血糖水平控制不足。本研究使用各种机器学习算法预测女性2型糖尿病。在Kaggle上发布的加州大学欧文分校糖尿病数据集被用于分析。方法:数据集包括预测2型糖尿病的8个危险因素,包括年龄、收缩压、血糖、体重指数、胰岛素、皮肤厚度、糖尿病谱系功能和妊娠。数据可视化使用R语言,研究考虑的算法有Logistic回归、支持向量机、决策树和极端梯度增强。本文还介绍了这些算法在各种分类指标上的性能分析,考虑到曲线下面积和接收者操作特征得分对于极端梯度提升(85%)是最好的,其次是支持向量机和决策树。结果:Logistic回归表现不佳。但是决策树和极端梯度增强在所有分类指标上都表现出很好的性能。但支持向量机的支持值较低;因此,它不能被称为一个好的分类器。该模型显示,2型糖尿病最显著的预测因子与血糖水平密切相关,与体重指数中等相关,而年龄、皮肤厚度、收缩压、胰岛素、妊娠和谱系功能不显著。这种类型的实时分析已经证明,与男性相比,女性2型糖尿病的症状完全不同,这突出了女性血糖水平和体重指数的重要性。结论:2型糖尿病的预测有助于公共卫生专业人员通过建议女性合理的食物摄入和调整生活方式活动以及良好的健身管理来控制血糖水平和体重指数。因此,卫生保健系统应特别关注女性糖尿病状况,以减少疾病恶化和其他相关症状。本研究试图从女性的行为和生理状况来预测2型糖尿病的发生。
{"title":"Using Machine Learning and Artificial Intelligence to Predict Diabetes Mellitus among Women Population.","authors":"Ali Mamoon Alfalki","doi":"10.2174/1573399820666230605160212","DOIUrl":"10.2174/1573399820666230605160212","url":null,"abstract":"<p><strong>Background: </strong>Diabetes Mellitus is a chronic health condition (long-lasting) due to inadequate control of blood levels of glucose. This study presents a prediction of Type 2 Diabetes Mellitus among women using various Machine Learning Algorithms deployed to predict the diabetic condition. A University of California Irvine Diabetes Mellitus Dataset posted in Kaggle was used for analysis.</p><p><strong>Methods: </strong>The dataset included eight risk factors for Type 2 Diabetes Mellitus prediction, including Age, Systolic Blood Pressure, Glucose, Body Mass Index, Insulin, Skin Thickness, Diabetic Pedigree Function, and Pregnancy. R language was used for the data visualization, while the algorithms considered for the study are Logistic Regression, Support Vector Machines, Decision Trees and Extreme Gradient Boost. The performance analysis of these algorithms on various classification metrics is also presented here, considering the Area Under the Curve and Receiver Operating Characteristics score is the best for Extreme Gradient Boost with 85%, followed by Support Vector Machines and Decision Trees.</p><p><strong>Results: </strong>The Logistic Regression is showing low performance. But the Decision Trees and Extreme Gradient Boost show promising performance against all the classification metrics. But the Support Vector Machines offers a lower support value; hence it cannot be claimed to be a good classifier. The model showed that the most significant predictors of Type 2 Diabetes Mellitus were strongly correlated with Glucose Levels and mediumly correlated with Body Mass Index, whereas Age, Skin Thickness, Systolic Blood Pressure, Insulin, Pregnancy, and Pedigree Function were less significant. This type of real-time analysis has proved that the symptoms of Type 2 Diabetes Mellitus in women fall entirely different compared to men, which highlights the importance of Glucose Levels and Body Mass Index in women.</p><p><strong>Conclusion: </strong>The prediction of Type 2 Diabetes Mellitus helps public health professionals to help people by suggesting proper food intake and adjusting lifestyle activities with good fitness management in women to make glucose levels and body mass index controlled. Therefore, the healthcare systems should give special attention to diabetic conditions in women to reduce exacerbations of the disease and other associated symptoms. This work attempts to predict the occurrence of Type 2 Diabetes Mellitus among women on their behavioral and biological conditions.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"35-46"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9652745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial. 二甲双胍、替尼格列汀和格列美脲联合治疗2型糖尿病的有效性和安全性:一项准实验性临床试验。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998292943240730115310
Rajesh Kumar Manchi, Santenna Chenchula, Manchi Haritha

Introduction: Type 2 Diabetes Mellitus (T2DM) accounts for more than 95% of all diabetes cases and is a leading cause of disability and death. This study aimed to evaluate the effectiveness and safety of a combination therapy involving metformin, teneligliptin, and glimepiride in patients diagnosed with T2DM.

Methods: The present quasi-experimental clinical trial involved 300 adult T2DM patients. They were divided into three groups: Group 1 (Metformin; n=100), Group 2 (Metformin + Teneligliptin; n=100), and Group 3 (Metformin + Teneligliptin +; n=100). Along with demographic data, we collected information on HbA1c, FBS, and PPBS levels, as well as fasting insulin, CPeptide, HOMA-IR, QUICKI-IR, and lipid, renal, and hepatic profiles at baseline and after 3, 6, and 12 months. Data analysis was performed using SPSS 21.0 software.

Results: A total of 300 patients participated in the study. At the end of 12 months, triple-drug therapy achieved significant glycemic control (HbA1c: 6.56±0.50%; P<0.0001) and reduced FBS (7.6±1.41 mg/dl; P<0.0001), PPBS (9.39±2.14 mg/dl; P<0.0001), and fasting insulin (11.26±2.5 IU; P<0.0001), C-peptide (2.01±2.29 ng/ml; P<0.0001), and insulin resistance by HOMA-IR (3.74±0.7; P<0.0001). Favorable lipid profiles (P<0.0001) were noted versus other groups. Despite renal and hepatic profile variations, values remained within the normal range.

Conclusion: The combination of teneligliptin with metformin and glimepiride in T2DM patients demonstrated significant improvements in glycaemic control, reduced insulin resistance, and positive effects on lipid, renal, and hepatic profiles. Importantly, the therapy did not result in serious adverse drug reactions, such as hypoglycemia. We need more RCTs to substantiate these findings.

2型糖尿病(T2DM)占所有糖尿病病例的95%以上,是导致残疾和死亡的主要原因。本研究旨在评估二甲双胍、替尼格列汀和格列美脲联合治疗T2DM患者的有效性和安全性。方法:拟实验性临床试验纳入300例成人T2DM患者。患者分为三组:第一组(二甲双胍;n=100),第二组(二甲双胍+ Teneligliptin;n=100),第三组(二甲双胍+ Teneligliptin +;n = 100)。除了人口统计数据,我们还收集了基线和3、6和12个月后的HbA1c、FBS和PPBS水平,以及空腹胰岛素、CPeptide、HOMA-IR、QUICKI-IR、脂质、肾脏和肝脏的信息。数据分析采用SPSS 21.0软件。结果:共300例患者参与研究。在12个月结束时,三联药物治疗取得了显著的血糖控制(HbA1c: 6.56±0.50%;结论:替尼格列汀联合二甲双胍和格列美脲治疗T2DM患者可显著改善血糖控制,降低胰岛素抵抗,并对血脂、肾脏和肝脏有积极影响。重要的是,该疗法没有导致严重的药物不良反应,如低血糖。我们需要更多的随机对照试验来证实这些发现。
{"title":"Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial.","authors":"Rajesh Kumar Manchi, Santenna Chenchula, Manchi Haritha","doi":"10.2174/0115733998292943240730115310","DOIUrl":"10.2174/0115733998292943240730115310","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 Diabetes Mellitus (T2DM) accounts for more than 95% of all diabetes cases and is a leading cause of disability and death. This study aimed to evaluate the effectiveness and safety of a combination therapy involving metformin, teneligliptin, and glimepiride in patients diagnosed with T2DM.</p><p><strong>Methods: </strong>The present quasi-experimental clinical trial involved 300 adult T2DM patients. They were divided into three groups: Group 1 (Metformin; n=100), Group 2 (Metformin + Teneligliptin; n=100), and Group 3 (Metformin + Teneligliptin +; n=100). Along with demographic data, we collected information on HbA1c, FBS, and PPBS levels, as well as fasting insulin, CPeptide, HOMA-IR, QUICKI-IR, and lipid, renal, and hepatic profiles at baseline and after 3, 6, and 12 months. Data analysis was performed using SPSS 21.0 software.</p><p><strong>Results: </strong>A total of 300 patients participated in the study. At the end of 12 months, triple-drug therapy achieved significant glycemic control (HbA1c: 6.56±0.50%; P<0.0001) and reduced FBS (7.6±1.41 mg/dl; P<0.0001), PPBS (9.39±2.14 mg/dl; P<0.0001), and fasting insulin (11.26±2.5 IU; P<0.0001), C-peptide (2.01±2.29 ng/ml; P<0.0001), and insulin resistance by HOMA-IR (3.74±0.7; P<0.0001). Favorable lipid profiles (P<0.0001) were noted versus other groups. Despite renal and hepatic profile variations, values remained within the normal range.</p><p><strong>Conclusion: </strong>The combination of teneligliptin with metformin and glimepiride in T2DM patients demonstrated significant improvements in glycaemic control, reduced insulin resistance, and positive effects on lipid, renal, and hepatic profiles. Importantly, the therapy did not result in serious adverse drug reactions, such as hypoglycemia. We need more RCTs to substantiate these findings.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"102-111"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Qatar's Silent Epidemic: A Comprehensive Meta-analysis on the Prevalence of Metabolic Syndrome. 卡塔尔的无声流行病:关于代谢综合征患病率的综合元分析。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998286706240129074153
Sarah Aqel, Jamil Ahmad, Sebawe Syaj, Majd N Daoud, Bashar Araiqat

Background: Metabolic syndrome comprises various conditions like abdominal obesity, insulin resistance, elevated triglyceride levels, reduced HDL, and high blood pressure, which pose significant health challenges globally. It's imperative to determine its prevalence in specific populations to formulate effective preventive measures.

Objective: This systematic review and meta-analysis aimed to determine the prevalence of metabolic syndrome in the Qatari population.

Methods: Using the PRISMA guidelines, a systematic search was executed on PubMed until July 2023 with keywords "Metabolic syndrome" and "Qatar." Eligibility criteria included human subjects, studies assessing metabolic syndrome components, and research conducted in Qatar or on Qatari subjects. The quality of the studies was evaluated using the Newcastle-Ottawa Scale (NOS). Pooled prevalence rates were calculated using the inverse variance weighting metaanalysis.

Results: Out of 237 studies, 14 met our inclusion criteria, with a combined sample size of 14,772 from the Qatari population. The overall pooled prevalence of metabolic syndrome was 26%. The ATP III and IDF criteria exhibited significant differences in prevalence rates, with the IDF criteria showing a higher prevalence. Patients in the age of 40 or older demonstrated a higher prevalence compared to the younger group. Studies post-2018 reported a decreasing trend in metabolic syndrome prevalence.

Conclusion: The prevalence of metabolic syndrome in the Qatari population is comparable to rates in the Middle East. The study underscores the need for tailored interventions and strategies, especially targeting the older age group. Continuous research and monitoring are essential to track and understand the disease's progression in Qatar.

背景:代谢综合征包括腹部肥胖、胰岛素抵抗、甘油三酯水平升高、高密度脂蛋白降低和高血压等多种病症,对全球健康构成重大挑战。当务之急是确定其在特定人群中的患病率,以制定有效的预防措施:本系统综述和荟萃分析旨在确定代谢综合征在卡塔尔人口中的患病率:方法:采用 PRISMA 指南,以 "代谢综合征 "和 "卡塔尔 "为关键词在 PubMed 上进行了系统检索,检索期至 2023 年 7 月。资格标准包括人类受试者、评估代谢综合征成分的研究、在卡塔尔进行的研究或以卡塔尔受试者为对象的研究。研究质量采用纽卡斯尔-渥太华量表(NOS)进行评估。采用逆方差加权荟萃分析法计算汇总患病率:在 237 项研究中,有 14 项符合我们的纳入标准,合计样本量为 14,772 个卡塔尔人。代谢综合征的总患病率为 26%。ATP III标准和IDF标准在患病率上有显著差异,其中IDF标准的患病率更高。与年轻群体相比,年龄≥40 岁的患病率更高。2018年后的研究报告显示,代谢综合征患病率呈下降趋势:卡塔尔人口的代谢综合征患病率与中东地区的患病率相当。这项研究强调了采取有针对性的干预措施和战略的必要性,尤其是针对老年群体。持续的研究和监测对于跟踪和了解该疾病在卡塔尔的进展情况至关重要。
{"title":"Qatar's Silent Epidemic: A Comprehensive Meta-analysis on the Prevalence of Metabolic Syndrome.","authors":"Sarah Aqel, Jamil Ahmad, Sebawe Syaj, Majd N Daoud, Bashar Araiqat","doi":"10.2174/0115733998286706240129074153","DOIUrl":"10.2174/0115733998286706240129074153","url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome comprises various conditions like abdominal obesity, insulin resistance, elevated triglyceride levels, reduced HDL, and high blood pressure, which pose significant health challenges globally. It's imperative to determine its prevalence in specific populations to formulate effective preventive measures.</p><p><strong>Objective: </strong>This systematic review and meta-analysis aimed to determine the prevalence of metabolic syndrome in the Qatari population.</p><p><strong>Methods: </strong>Using the PRISMA guidelines, a systematic search was executed on PubMed until July 2023 with keywords \"Metabolic syndrome\" and \"Qatar.\" Eligibility criteria included human subjects, studies assessing metabolic syndrome components, and research conducted in Qatar or on Qatari subjects. The quality of the studies was evaluated using the Newcastle-Ottawa Scale (NOS). Pooled prevalence rates were calculated using the inverse variance weighting metaanalysis.</p><p><strong>Results: </strong>Out of 237 studies, 14 met our inclusion criteria, with a combined sample size of 14,772 from the Qatari population. The overall pooled prevalence of metabolic syndrome was 26%. The ATP III and IDF criteria exhibited significant differences in prevalence rates, with the IDF criteria showing a higher prevalence. Patients in the age of 40 or older demonstrated a higher prevalence compared to the younger group. Studies post-2018 reported a decreasing trend in metabolic syndrome prevalence.</p><p><strong>Conclusion: </strong>The prevalence of metabolic syndrome in the Qatari population is comparable to rates in the Middle East. The study underscores the need for tailored interventions and strategies, especially targeting the older age group. Continuous research and monitoring are essential to track and understand the disease's progression in Qatar.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"47-57"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach. 解开纽带:2 型糖尿病与帕金森病--一种基于纳米的靶向给药方法。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998291968240429111357
Sourav De, Sabyasachi Banerjee, Pallabita Rakshit, Subhasis Banerjee, S K Ashok Kumar

The link between Type 2 Diabetes (T2DM) and Parkinson's Disease (PD) dates back to the early 1960s, and ongoing research is exploring this association. PD is linked to dysregulation of dopaminergic pathways, neuroinflammation, decreased PPAR-γ coactivator 1-α, increased phosphoprotein enriched in diabetes, and accelerated α-Syn amyloid fibril production caused by T2DM. This study aims to comprehensively evaluate the T2DM-PD association and risk factors for PD in T2DM individuals. The study reviews existing literature using reputable sources like Scopus, ScienceDirect, and PubMed, revealing a significant association between T2DM and worsened PD symptoms. Genetic profiles of T2DM-PD individuals show similarities, and potential risk factors include insulin-resistance and dysbiosis of the gut-brain microbiome. Anti-diabetic drugs exhibit neuroprotective effects in PD, and nanoscale delivery systems like exosomes, micelles, and liposomes show promise in enhancing drug efficacy by crossing the Blood-Brain Barrier (BBB). Brain targeting for PD uses exosomes, micelles, liposomes, dendrimers, solid lipid nanoparticles, nano-sized polymers, and niosomes to improve medication and gene therapy efficacy. Surface modification of nanocarriers with bioactive compounds (such as angiopep, lactoferrin, and OX26) enhances α-Syn conjugation and BBB permeability. Natural exosomes, though limited, hold potential for investigating DM-PD pathways in clinical research. The study delves into the underlying mechanisms of T2DM and PD and explores current therapeutic approaches in the field of nano-based targeted drug delivery. Emphasis is placed on resolved and ongoing issues in understanding and managing both conditions.

2 型糖尿病(T2DM)与帕金森病(PD)之间的联系可追溯到 20 世纪 60 年代初,目前正在对这种联系进行研究。帕金森病与多巴胺能通路失调、神经炎症、PPAR-γ辅助激活剂1-α减少、糖尿病富集的磷蛋白增加以及T2DM导致的α-Syn淀粉样纤维生成加速有关。本研究旨在全面评估 T2DM 与 PD 的关联以及 T2DM 患者 PD 的风险因素。研究利用Scopus、ScienceDirect和PubMed等权威来源对现有文献进行了回顾,发现T2DM与帕金森病症状恶化之间存在显著关联。T2DM-PD患者的遗传特征显示出相似性,潜在的风险因素包括胰岛素抵抗和肠脑微生物组失调。抗糖尿病药物对帕金森病具有神经保护作用,外泌体、胶束和脂质体等纳米级递送系统有望通过穿越血脑屏障(BBB)提高药物疗效。针对帕金森病的脑靶向治疗利用外泌体、胶束、脂质体、树枝状分子、固体脂质纳米颗粒、纳米聚合物和niosomes来提高药物和基因治疗的疗效。用生物活性化合物(如 angiopep、乳铁蛋白和 OX26)对纳米载体进行表面修饰,可增强 α-Syn 连接和 BBB 渗透性。天然外泌体虽然数量有限,但具有在临床研究中调查 DM-PD 途径的潜力。本研究深入探讨了 T2DM 和 PD 的基本机制,并探讨了纳米靶向给药领域的现有治疗方法。重点是在理解和管理这两种疾病方面已经解决和正在解决的问题。
{"title":"Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.","authors":"Sourav De, Sabyasachi Banerjee, Pallabita Rakshit, Subhasis Banerjee, S K Ashok Kumar","doi":"10.2174/0115733998291968240429111357","DOIUrl":"10.2174/0115733998291968240429111357","url":null,"abstract":"<p><p>The link between Type 2 Diabetes (T2DM) and Parkinson's Disease (PD) dates back to the early 1960s, and ongoing research is exploring this association. PD is linked to dysregulation of dopaminergic pathways, neuroinflammation, decreased PPAR-γ coactivator 1-α, increased phosphoprotein enriched in diabetes, and accelerated α-Syn amyloid fibril production caused by T2DM. This study aims to comprehensively evaluate the T2DM-PD association and risk factors for PD in T2DM individuals. The study reviews existing literature using reputable sources like Scopus, ScienceDirect, and PubMed, revealing a significant association between T2DM and worsened PD symptoms. Genetic profiles of T2DM-PD individuals show similarities, and potential risk factors include insulin-resistance and dysbiosis of the gut-brain microbiome. Anti-diabetic drugs exhibit neuroprotective effects in PD, and nanoscale delivery systems like exosomes, micelles, and liposomes show promise in enhancing drug efficacy by crossing the Blood-Brain Barrier (BBB). Brain targeting for PD uses exosomes, micelles, liposomes, dendrimers, solid lipid nanoparticles, nano-sized polymers, and niosomes to improve medication and gene therapy efficacy. Surface modification of nanocarriers with bioactive compounds (such as angiopep, lactoferrin, and OX26) enhances α-Syn conjugation and BBB permeability. Natural exosomes, though limited, hold potential for investigating DM-PD pathways in clinical research. The study delves into the underlying mechanisms of T2DM and PD and explores current therapeutic approaches in the field of nano-based targeted drug delivery. Emphasis is placed on resolved and ongoing issues in understanding and managing both conditions.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"32-58"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Technology for the Management of Type 1 Diabetes Mellitus in Saudi Arabia and MENA Region: A Systematic Review. 沙特阿拉伯和中东及北非地区 1 型糖尿病管理技术:系统回顾。
IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-01-01 DOI: 10.2174/0115733998295755240416060913
Ayman Al Hayek, Mohamed A Al Dawish

Background: Diabetes technology in the form of digital health or medical devices holds a promise for improving the quality of life and glycemic outcomes. A comprehensive insight into diabetes technology and its impact in Saudi Arabia and the MENA region may improve type 1 diabetes mellitus (T1DM) management.

Objective: This study aimed to assess the impact of different DM-specific technologies: Insulin pump therapy, continuous glucose monitoring (CGM), and automated insulin delivery system in terms of glycemic control and QoL among T1DM patients in Saudi Arabia and the MENA region.

Method: A systematic literature search was performed in PubMed and Scopus from 2005 until August 2023. The search was based on the PICO strategy, focusing on T1DM patients, diabetes technology, and QoL. The inclusion criteria were studies illustrating the effect of diabetes technologies on glycemic control or quality of life or both among T1DM patients. Systematic reviews, books, letters, or studies, including type 2 diabetes mellitus, were excluded.

Results: From 101 articles, eighteen studies were duplicated, and thirty-three studies were excluded after reading the title and abstract. Of the 50 articles analyzed, twenty-five articles did not meet the inclusion criteria. Therefore, 25 articles involving a total of 3088 participants were enrolled in the study. It was shown that a continuous glucose monitoring system and continuous subcutaneous insulin infusion improved the glycemic control and the QoL of T1DM patients.

Conclusion: There was a positive impact of insulin pumps, continuous glucose monitoring (CGM) systems, and telemedicine in achieving optimal glucose control and better QoL. Further studies are recommended to clarify the significant role of advanced diabetes technologies.

背景:数字健康或医疗设备形式的糖尿病技术有望改善生活质量和血糖结果。全面了解糖尿病技术及其在沙特阿拉伯和中东及北非地区的影响可改善 1 型糖尿病(T1DM)的管理:本研究旨在评估胰岛素泵疗法、连续血糖监测(CGM)和胰岛素自动给药系统等不同糖尿病专用技术对沙特阿拉伯和中东及北非地区 T1DM 患者血糖控制和 QoL 的影响:方法:在 PubMed 和 Scopus 上进行了系统的文献检索,检索时间为 2005 年至 2023 年 8 月。搜索基于 PICO 策略,重点关注 T1DM 患者、糖尿病技术和 QoL。纳入标准是说明糖尿病技术对 T1DM 患者血糖控制或生活质量或两者影响的研究。不包括系统综述、书籍、信件或包括 2 型糖尿病在内的研究:在 101 篇文章中,有 18 篇研究重复,有 33 篇研究在阅读了标题和摘要后被排除。在分析的 50 篇文章中,有 25 篇不符合纳入标准。因此,本研究共纳入了 25 篇文章,涉及 3088 名参与者。研究表明,持续血糖监测系统和持续皮下注射胰岛素改善了 T1DM 患者的血糖控制和 QoL:结论:胰岛素泵、连续血糖监测系统和远程医疗对实现最佳血糖控制和更好的 QoL 有积极影响。建议开展进一步研究,以明确先进糖尿病技术的重要作用。
{"title":"Technology for the Management of Type 1 Diabetes Mellitus in Saudi Arabia and MENA Region: A Systematic Review.","authors":"Ayman Al Hayek, Mohamed A Al Dawish","doi":"10.2174/0115733998295755240416060913","DOIUrl":"10.2174/0115733998295755240416060913","url":null,"abstract":"<p><strong>Background: </strong>Diabetes technology in the form of digital health or medical devices holds a promise for improving the quality of life and glycemic outcomes. A comprehensive insight into diabetes technology and its impact in Saudi Arabia and the MENA region may improve type 1 diabetes mellitus (T1DM) management.</p><p><strong>Objective: </strong>This study aimed to assess the impact of different DM-specific technologies: Insulin pump therapy, continuous glucose monitoring (CGM), and automated insulin delivery system in terms of glycemic control and QoL among T1DM patients in Saudi Arabia and the MENA region.</p><p><strong>Method: </strong>A systematic literature search was performed in PubMed and Scopus from 2005 until August 2023. The search was based on the PICO strategy, focusing on T1DM patients, diabetes technology, and QoL. The inclusion criteria were studies illustrating the effect of diabetes technologies on glycemic control or quality of life or both among T1DM patients. Systematic reviews, books, letters, or studies, including type 2 diabetes mellitus, were excluded.</p><p><strong>Results: </strong>From 101 articles, eighteen studies were duplicated, and thirty-three studies were excluded after reading the title and abstract. Of the 50 articles analyzed, twenty-five articles did not meet the inclusion criteria. Therefore, 25 articles involving a total of 3088 participants were enrolled in the study. It was shown that a continuous glucose monitoring system and continuous subcutaneous insulin infusion improved the glycemic control and the QoL of T1DM patients.</p><p><strong>Conclusion: </strong>There was a positive impact of insulin pumps, continuous glucose monitoring (CGM) systems, and telemedicine in achieving optimal glucose control and better QoL. Further studies are recommended to clarify the significant role of advanced diabetes technologies.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"75-92"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current diabetes reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1